MedTrace Logo

A Clinical Trial Comparing the Efficacy and Safety of Exubera® and Lantus®

NCT00391027 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 261

Last updated 2015-07-23

Study results available
· View outcomes & findings →

Summary

To compare efficacy and safety of Exubera® vs Lantus® in patients with type 2 diabetes mellitus.

Conditions

  • Diabetes Mellitus, Type 2

Interventions

DRUG

Insulin Glargine (Lantus®)

Patient will be randomized to Lantus® while remaining on pre-study oral hypoglycemic agents.

DRUG

Inhaled Human Insulin (Exubera®)

Patient will be randomized inhaled insulin while remaining on pre-study oral hypoglycemic agents.

Sponsors & Collaborators

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
30 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-12-31
Primary Completion
2008-08-31
Completion
2008-08-31

Countries

  • Belgium
  • Finland
  • France
  • Germany
  • Netherlands
  • Norway
  • Poland
  • Spain
  • Sweden
  • Switzerland

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00391027 on ClinicalTrials.gov